ConsoneAI, "Predicting Toxicity, Protecting Lives"
Our Story
Revolutionizing Patient Experience
ConsoneAI is a pioneering TechBio company dedicated to revolutionizing drug development and chemical safety. With a focus on enhancing human safety we leverage cutting-edge computational models and AI technology to predict the toxicity of new chemicals.
By reducing the reliance on animal testing and supporting industry 3rs commitment to Reduce, Replace, Refine. We accelerate the development of safer drugs and chemicals, making it more efficient and cost-effective. Our commitment extends to supporting the industry in transitioning towards safer practices, ultimately leading to the creation of better and faster drug solutions.
Our Service
DioScor
DioScor is our product to aid drug development by predicting patient outcomes from Preclinical through to clinical stages. Our technology is based on:
Toxicity Database
We have curated and collated over 80k+ chemical compounds with toxicity data from animal and human studies.
Platform
Our pipeline involves the use of deep learning to model molecular structures and toxicity. Instead of training a single model for all predictions, our approach involves training models that are bespoke to each compound based on chemical similarity. Our predictions are focussed on toxicity at the level of the organism rather than molecular property prediction.
Innovative Solutions
Integrating ConsoneAI into your drug development process offers several compelling innovative solutions and advantages:
Reduction in Animal Testing: ConsoneAI's AI software platform will reduce the need for animal testing by predicting the toxicity of new chemicals, aligning with ethical standards and regulatory guidelines and supporting NC3Rs requirements.
Increased Safety and Efficacy: By predicting potential safety issues early in the development process, ConsoneAI helps identify and mitigate risks, leading to the development of safer and more effective drugs.
Regulatory Compliance: ConsoneAI's platform facilitates compliance with global regulatory changes and supports Investigational New Drug (IND) applications with robust toxicity data.
Cutting Edge
Cutting edge technology allows users to fail a molecule fast, redesign the molecule earlier or continue by streamlining testing by reducing cost and animal testing.
Cost Efficiency: Traditional drug development is expensive and time-consuming. ConsoneAI streamlines this process by providing early insights into drug toxicity, which can reduce costly late-stage failures and overall development costs.
Accelerated Development Timeline: ConsoneAI's predictive capabilities enable faster decision-making and optimization of drug candidates, shortening the time from discovery to clinical trials and, ultimately, to market.
Enhanced Success Rates: With approximately 92% of drugs failing due to safety and efficacy issues, ConsoneAI's technology improves the likelihood of success by identifying viable candidates earlier and refining them more effectively.